112 related articles for article (PubMed ID: 2702975)
1. Pharmacokinetics of weekly low dose doxorubicin.
Frenay M; Milano G; Renee N; Pons D; Khater R; François E; Thyss A; Namer M
Eur J Cancer Clin Oncol; 1989 Feb; 25(2):191-5. PubMed ID: 2702975
[TBL] [Abstract][Full Text] [Related]
2. Total, renal and hepatic clearances of doxorubicin and formation clearance of doxorubicinol in patients with breast cancer: Estimation of doxorubicin hepatic extraction ratio.
Pippa LF; Oliveira ML; Rocha A; de Andrade JM; Lanchote VL
J Pharm Biomed Anal; 2020 Jun; 185():113231. PubMed ID: 32163849
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetics of doxorubicin and doxorubicinol in patients diagnosed with non-Hodgkin's lymphoma.
Pérez-Blanco JS; Santos-Buelga D; Fernández de Gatta MD; Hernández-Rivas JM; Martín A; García MJ
Br J Clin Pharmacol; 2016 Dec; 82(6):1517-1527. PubMed ID: 27447545
[TBL] [Abstract][Full Text] [Related]
4. Pharmacology and clinical toxicity of 4'-iodo-4'-deoxydoxorubicin: an example of successful application of pharmacokinetics to dose escalation in phase I trials.
Gianni L; Viganò L; Surbone A; Ballinari D; Casali P; Tarella C; Collins JM; Bonadonna G
J Natl Cancer Inst; 1990 Mar; 82(6):469-77. PubMed ID: 2313718
[TBL] [Abstract][Full Text] [Related]
5. Phase I pharmacokinetic study of cyclosporin A combined with doxorubicin.
Erlichman C; Moore M; Thiessen JJ; Kerr IG; Walker S; Goodman P; Bjarnason G; DeAngelis C; Bunting P
Cancer Res; 1993 Oct; 53(20):4837-42. PubMed ID: 8402670
[TBL] [Abstract][Full Text] [Related]
6. Comparative pharmacokinetics of doxorubicin given by three different schedules with equal dose intensity in patients with breast cancer.
Twelves CJ; Dobbs NA; Aldhous M; Harper PG; Rubens RD; Richards MA
Cancer Chemother Pharmacol; 1991; 28(4):302-7. PubMed ID: 1879047
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and cardiotoxicity of doxorubicin and its secondary alcohol metabolite in rats.
Zeng X; Cai H; Yang J; Qiu H; Cheng Y; Liu M
Biomed Pharmacother; 2019 Aug; 116():108964. PubMed ID: 31102935
[TBL] [Abstract][Full Text] [Related]
8. [Pharmacokinetic profile of high-dose doxorubicin administered during a 6 h intravenous infusion in breast cancer patients].
Wihlm J; Limacher JM; Levêque D; Duclos B; Dufour P; Bergerat JP; Methlin G
Bull Cancer; 1997 Jun; 84(6):603-8. PubMed ID: 9295863
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of doxorubicin and its active metabolite in patients with normal renal function and in patients on hemodialysis.
Yoshida H; Goto M; Honda A; Nabeshima T; Kumazawa T; Inagaki J; Yamanaka N; Ota K
Cancer Chemother Pharmacol; 1994; 33(6):450-4. PubMed ID: 8137454
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic evaluation of doxorubicin plasma levels in normal and overweight patients with breast cancer and simulation of dose adjustment by different indexes of body mass.
Barpe DR; Rosa DD; Froehlich PE
Eur J Pharm Sci; 2010 Nov; 41(3-4):458-63. PubMed ID: 20688160
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of Bcl-2 antisense oligonucleotide (G3139) combined with doxorubicin in SCID mice bearing human breast cancer solid tumor xenografts.
Lopes de Menezes DE; Mayer LD
Cancer Chemother Pharmacol; 2002 Jan; 49(1):57-68. PubMed ID: 11855753
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of iododoxorubicin in the rat, dog, and monkey.
Edwards DM; Marrari P; Efthymiopoulos C; Basileo G; Fraier D; Pianezzola E; Strolin-Benedetti M
Drug Metab Dispos; 1991; 19(5):938-45. PubMed ID: 1686240
[TBL] [Abstract][Full Text] [Related]
13. Doxorubicin and doxorubicinol plasma concentrations and excretion in parotid saliva.
Bressolle F; Jacquet JM; Galtier M; Jourdan J; Donadio D; Rossi JF
Cancer Chemother Pharmacol; 1992; 30(3):215-8. PubMed ID: 1628370
[TBL] [Abstract][Full Text] [Related]
14. Phase I and pharmacokinetics studies of prochlorperazine 2-h i.v. infusion as a doxorubicin-efflux blocker.
Sridhar KS; Krishan A; Samy TS; Duncan RC; Sauerteig A; McPhee GV; Auguste ME; Benedetto PW
Cancer Chemother Pharmacol; 1994; 34(5):377-84. PubMed ID: 8070004
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of safety parameters and changes in serum concentration in liver transplant recipients treated with doxorubicin during the anhepatic period.
Kobayashi S; Wada H; Hama N; Akita H; Kawamoto K; Eguchi H; Umeshita K; Doki Y; Mori M; Nagano H
Cancer Chemother Pharmacol; 2013 Dec; 72(6):1325-33. PubMed ID: 24121480
[TBL] [Abstract][Full Text] [Related]
16. Plasma pharmacokinetics and pharmacodynamics of a new prodrug N-l-leucyldoxorubicin and its metabolites in a phase I clinical trial.
de Jong J; Geijssen GJ; Munniksma CN; Vermorken JB; van der Vijgh WJ
J Clin Oncol; 1992 Dec; 10(12):1897-906. PubMed ID: 1453205
[TBL] [Abstract][Full Text] [Related]
17. Prochlorperazine as a doxorubicin-efflux blocker: phase I clinical and pharmacokinetics studies.
Sridhar KS; Krishan A; Samy TS; Sauerteig A; Wellham LL; McPhee G; Duncan RC; Anac SY; Ardalan B; Benedetto PW
Cancer Chemother Pharmacol; 1993; 31(6):423-30. PubMed ID: 8453681
[TBL] [Abstract][Full Text] [Related]
18. Doxorubicin weekly low dose administration: in vitro cytotoxicity generated by the typical pharmacokinetic profile.
Milano G; Cassuto-Viguier E; Fischel JL; Formento P; Renée N; Frenay M; Thyss A; Namer M
Eur J Cancer; 1992; 28A(11):1881-5. PubMed ID: 1389531
[TBL] [Abstract][Full Text] [Related]
19. Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer.
Gianni L; Viganò L; Locatelli A; Capri G; Giani A; Tarenzi E; Bonadonna G
J Clin Oncol; 1997 May; 15(5):1906-15. PubMed ID: 9164201
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and metabolism of iodo-doxorubicin and doxorubicin in humans.
Mross K; Mayer U; Hamm K; Burk K; Hossfeld DK
Eur J Clin Pharmacol; 1990; 39(5):507-13. PubMed ID: 2076745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
